Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 2, Issue 2, July-Sept, 2025
Page No.: 16-23

Review

Overcoming Multidrug Resistance in Cancer: Novel Strategies and Future Directions

Shipra Omar

Assistant Professor, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun Uttarakhand, 248001

Corresponding Author:
Shipra Omar

Email:
shipra.omar.28@gmail.com

DOI: *10.62896/cplr.2.3.03*

Conflict of interest: *NIL*

Article History
Received: 12/07/2025
Accepted: 28/08/2025
Published: 10/09/2025

Abstract:
Multidrug resistance (MDR) remains one of the most significant challenges in cancer therapy, often leading to treatment failure and poor clinical outcomes. MDR occurs due to the ability of cancer cells to expel anticancer drugs through mechanisms such as overexpression of efflux pumps, enhanced drug detoxification, altered drug targets, and evasion of cell death pathways. As a result, the effectiveness of many chemotherapeutic agents is diminished. Recent advancements in cancer research have identified novel strategies aimed at overcoming MDR, including the development of inhibitors targeting efflux transporters, nanoparticles for targeted drug delivery, gene therapy, and combination therapies that enhance the efficacy of traditional drugs. Additionally, immunotherapy and personalized medicine approaches have shown promise in bypassing MDR mechanisms. This paper provides a comprehensive review of these innovative strategies, evaluates their current clinical applications, and explores future directions in the fight against multidrug-resistant cancer. The integration of these novel strategies holds the potential to revolutionize cancer treatment, providing more effective and targeted therapies for patients.

Keywords: Multidrug resistance, cancer therapy, efflux pumps, drug delivery, nanoparticles, gene therapy, combination therapy, immunotherapy, personalized medicine, chemotherapy.

1.1 Introduction:

Cancer remains one of the leading causes of mortality worldwide, with treatment strategies primarily relying on chemotherapy, radiotherapy, and more recently, targeted therapies and immunotherapies. While these treatments have shown significant efficacy in many cases, the emergence of multidrug resistance (MDR) in cancer cells presents a major obstacle to successful treatment. MDR occurs when cancer cells develop resistance to a wide range of chemotherapeutic agents, rendering standard treatment protocols ineffective and contributing to poor prognosis in many cancer patients.(1)

The mechanisms behind MDR are complex and multifactorial, involving both intrinsic and acquired resistance pathways. One of the most prominent mechanisms is the overexpression of efflux pumps, such as P-glycoprotein (P-gp), which actively expel chemotherapeutic drugs from the cancer cells, thereby reducing their intracellular concentrations and effectiveness. Other mechanisms include changes in drug metabolism, mutations in drug targets, alterations in apoptotic pathways, and enhanced DNA repair capabilities.

Given the critical role MDR plays in treatment failure, overcoming resistance has become a major focus of cancer research. Researchers are exploring a variety of strategies to combat MDR, ranging from the development of novel chemotherapeutic agents and inhibitors targeting drug efflux pumps to the use of advanced drug delivery systems that improve the targeting and uptake of drugs in resistant cancer cells. In addition, innovative approaches such as

gene therapy, combination treatments, and immunotherapies offer new hope in bypassing or reversing MDR.(2)

This paper aims to provide a comprehensive review of the latest advancements in overcoming MDR in cancer, highlighting the most promising novel strategies and future directions in the field. By understanding the mechanisms of MDR and exploring emerging therapeutic approaches, we can pave the way for more effective cancer treatments, improving survival rates and quality of life for patients facing multidrug-resistant cancers.

1.2 Introduction to Multidrug Resistance in Cancer

Multidrug resistance (MDR) is a phenomenon in which cancer cells develop resistance to multiple chemotherapy drugs that are structurally and functionally unrelated. This resistance significantly limits the effectiveness of chemotherapy and leads to poor clinical outcomes, contributing to treatment failure in cancer patients.(3) MDR is often acquired over time as cancer cells evolve and adapt to therapeutic pressures, resulting in the survival of resistant clones. The widespread prevalence of MDR in clinical oncology makes it a major hurdle in treating various types of cancer, including leukemia, breast cancer, and non-small cell lung cancer. Despite advancements in cancer therapies, MDR remains one of the most challenging problems, emphasizing the need for innovative strategies to overcome or circumvent this resistance and improve treatment outcomes for patients.(4)

1.3 Mechanisms of Multidrug Resistance in Cancer Cells

MDR in cancer cells is driven by several complex and interrelated mechanisms, which can be broadly categorized into intrinsic and acquired resistance pathways. Intrinsic resistance refers to the natural ability of certain cancer cells to resist chemotherapy from the outset, often due to their genetic makeup.(5) Acquired resistance develops over time as cancer cells are exposed to chemotherapeutic agents, leading to adaptive changes that confer resistance. The primary mechanisms of MDR include the overexpression of drug efflux pumps, altered drug metabolism, mutation of drug targets, and enhanced DNA repair mechanisms. In addition, changes in cellular apoptotic pathways, which prevent cell death despite DNA damage or drug-induced stress, contribute to the resistance phenotype. Understanding these mechanisms is crucial for developing new therapeutic strategies aimed at reversing or bypassing MDR and restoring the effectiveness of chemotherapy.(6)

1.4 The Role of Efflux Pumps in Drug Resistance

Efflux pumps play a central role in the development of MDR by actively transporting chemotherapy drugs out of cancer cells, reducing their intracellular concentrations and thus diminishing their cytotoxic effects. The most well-known efflux pump is P-glycoprotein (P-gp), a membrane transporter encoded by the ABCB1 gene.(7) Overexpression of P-gp and other members of the ATP-binding cassette (ABC) transporter family, such as multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP), is frequently observed in drug-resistant cancers. These pumps use energy from ATP hydrolysis to expel a wide range of chemotherapeutic agents, including anthracyclines, taxanes, and vinca alkaloids, from the cytoplasm into the extracellular space. As a result, the effective concentration of these drugs inside the tumor cells is reduced, rendering them less effective. The inhibition of efflux pumps has thus emerged as a promising strategy to combat MDR, by enhancing the intracellular accumulation of chemotherapeutic agents and improving their therapeutic efficacy.(8)

1.5 Alterations in Drug Metabolism and Their Contribution to MDR

Alterations in drug metabolism are another key mechanism contributing to multidrug resistance (MDR) in cancer cells. Cancer cells often exhibit changes in enzymes responsible for drug metabolism, including cytochrome P450 enzymes, glutathione S-transferases, and UDP-glucuronosyltransferases. These enzymes play a crucial role in the activation and detoxification of chemotherapeutic agents.(9) In many drug-resistant cancers, an overexpression of detoxifying enzymes results in the rapid inactivation or modification of drugs, reducing their efficacy. For example, certain enzymes may enhance the conjugation of drugs with glutathione, leading to their sequestration in less active forms and preventing them from exerting their therapeutic effects. Additionally, cancer cells can also increase the expression of enzymes that accelerate the metabolism of drugs to inactive metabolites, further decreasing drug effectiveness. The altered drug metabolism in MDR cells can be overcome by developing new inhibitors that target these metabolic pathways, allowing for better

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 2, Issue 2, July-Sept, 2025
Page No.: 16-23

retention of chemotherapeutic agents within the tumor cells.(10)

1.6 Targeting the Genetic Basis of Multidrug Resistance

The genetic alterations that underlie multidrug resistance in cancer cells are a central focus of research aimed at overcoming MDR. Genetic mutations and epigenetic changes can lead to alterations in the expression of key genes involved in drug transport, metabolism, apoptosis, and cell cycle regulation.(11) For instance, mutations in the P-glycoprotein gene or upregulation of drug efflux pumps can result in the loss of sensitivity to multiple drugs. Furthermore, mutations in tumor suppressor genes like p53, which regulates cell cycle progression and apoptosis, can allow cancer cells to survive despite drug-induced damage. Advances in genomic sequencing and CRISPR-based gene editing technologies have opened new avenues for understanding the genetic drivers of MDR. Targeting these genetic mutations—such as using gene silencing techniques or CRISPR/Cas9 to knock down drug-resistant genes—can help restore the sensitivity of cancer cells to chemotherapy. Genetic profiling of tumors can also help identify personalized treatments that specifically target the resistance mechanisms present in individual patients, potentially leading to more effective therapies.(12)

1.7 Enhanced DNA Repair Mechanisms and MDR

Cancer cells often develop enhanced DNA repair mechanisms, which play a critical role in the acquisition of MDR. These enhanced repair pathways allow the cancer cells to recover more rapidly from DNA damage caused by chemotherapeutic agents, thus reducing the effectiveness of the treatment.(13) One of the most commonly upregulated DNA repair mechanisms in MDR cancer cells is the nucleotide excision repair (NER) pathway, which is involved in repairing damage caused by drugs like platinum-based chemotherapies. Additionally, the base excision repair (BER) and homologous recombination repair (HRR) pathways can be more active in drug-resistant cells, allowing them to repair single-strand and double-strand DNA breaks induced by chemotherapy. Overexpression of DNA repair proteins, such as PARP (poly(ADP-ribose) polymerase), can further enhance the cell's ability to fix drug-induced DNA damage. Inhibiting these DNA repair pathways is a promising therapeutic strategy to overcome MDR, as it can sensitize resistant cancer cells to chemotherapy by preventing them from repairing the DNA damage induced by treatment.(14)

1.8 Impact of Tumor Microenvironment on Drug Resistance

The tumor microenvironment (TME) plays a crucial role in the development of multidrug resistance. The TME is a complex and dynamic environment consisting of tumor cells, immune cells, blood vessels, fibroblasts, and extracellular matrix components. This environment can influence the behavior of cancer cells, including their response to chemotherapy. Hypoxia, or low oxygen levels, within tumors is one of the most significant features of the TME that contributes to drug resistance.(15) Under hypoxic conditions, cancer cells often activate adaptive pathways that promote survival, including upregulation of efflux pumps and DNA repair mechanisms, while reducing the efficacy of chemotherapy. Additionally, the extracellular matrix in the TME can serve as a physical barrier, preventing drug penetration into the tumor tissue. Furthermore, cancer-associated fibroblasts and immune cells within the TME can release factors that promote the survival and drug resistance of cancer cells. Inflammation and the secretion of pro-survival cytokines can further contribute to MDR by activating signaling pathways that enhance drug resistance. Targeting the TME through strategies such as normalizing blood vessels, reducing hypoxia, or inhibiting stromal interactions holds potential for overcoming MDR and improving the effectiveness of cancer treatments.(16)

1.9 Nanoparticle-Based Drug Delivery Systems to Overcome MDR

Nanoparticle-based drug delivery systems have emerged as a promising strategy to overcome multidrug resistance (MDR) in cancer therapy. These nanocarriers, which can be composed of liposomes, dendrimers, polymers, or nanoparticles, offer several advantages over traditional drug delivery methods. They can be engineered to encapsulate chemotherapeutic agents, thereby protecting them from premature degradation and enhancing their stability. (17)Furthermore, nanoparticles can be designed to target drug-resistant cancer cells selectively by modifying their surface with ligands or antibodies that bind specifically to overexpressed receptors or antigens

on the tumor cells. This targeted approach increases the concentration of the drug at the tumor site, reducing the impact on healthy tissues and minimizing side effects. Additionally, nanoparticles can bypass drug efflux mechanisms by enhancing cellular uptake through endocytosis or other mechanisms. Some advanced nanoparticle-based systems also allow for the controlled release of drugs, ensuring sustained drug levels within the tumor, which can overcome the challenges posed by rapid drug clearance and resistance mechanisms. This innovative approach holds great promise in increasing the efficacy of chemotherapy and reversing MDR in cancer.(18)

1.10 Combination Therapy: A Strategy to Bypass MDR

Combination therapy, which involves the use of multiple drugs with different mechanisms of action, is an effective strategy to bypass multidrug resistance (MDR) in cancer treatment. By targeting multiple pathways involved in drug resistance simultaneously, combination therapy can prevent or overcome compensatory mechanisms that cancer cells use to evade the effects of a single drug.(19) For example, combining chemotherapy with inhibitors of efflux pumps or DNA repair enzymes can enhance the intracellular accumulation of drugs and prevent cancer cells from repairing the DNA damage caused by chemotherapy. Additionally, combining conventional chemotherapeutic agents with novel therapies, such as targeted drugs or immunotherapy, can create a synergistic effect that enhances the overall treatment response. The use of combination therapy has been shown to reduce the likelihood of resistance development, as it is more difficult for cancer cells to simultaneously acquire resistance to multiple agents. Clinical trials have demonstrated the efficacy of combination regimens in overcoming MDR in various cancers, including lung, breast, and colorectal cancers. This approach is an essential component of future cancer treatment strategies, as it can improve patient outcomes while minimizing the risk of recurrence.(20)

1.11 Gene Therapy and RNA Interference in Overcoming MDR

Gene therapy and RNA interference (RNAi) are promising approaches for overcoming multidrug resistance (MDR) by targeting the molecular mechanisms that drive resistance in cancer cells. Gene therapy involves the delivery of genetic material, such as genes encoding for proteins that can modulate drug resistance, directly into the tumor cells. This can include introducing genes that inhibit the expression of drug efflux pumps like P-glycoprotein, restore the function of tumor suppressor genes like p53, or enhance the tumor's sensitivity to chemotherapy.(21) RNA interference, on the other hand, uses small RNA molecules, such as small interfering RNA (siRNA) or microRNA (miRNA), to specifically silence the expression of genes responsible for MDR. For example, RNAi can be used to silence the genes encoding for efflux pumps or DNA repair proteins, reducing the cancer cell's ability to expel drugs or repair drug-induced damage. The development of RNA-based therapies has also been focused on targeting the signaling pathways involved in cell survival and apoptosis, which are often altered in MDR cancers. Although challenges in delivery methods and specificity remain, advances in nanoparticle-based delivery systems and viral vectors are making gene therapy and RNAi more feasible for clinical use, offering exciting new possibilities for overcoming MDR.(22)

1.12 Targeting Apoptotic Pathways to Combat MDR

Apoptosis, or programmed cell death, is a critical mechanism by which chemotherapy drugs exert their therapeutic effects. However, many cancer cells, especially those exhibiting multidrug resistance (MDR), develop the ability to evade apoptosis, allowing them to survive and proliferate despite treatment. One of the key factors in this evasion is the alteration of apoptotic signaling pathways.(23) For example, the overexpression of anti-apoptotic proteins, such as Bcl-2, and the downregulation of pro-apoptotic proteins, such as Bax, can block the activation of apoptosis in response to chemotherapy. Additionally, mutations in tumor suppressor genes like p53, which normally play a key role in inducing apoptosis in response to DNA damage, are frequently observed in MDR cancer cells. To combat MDR, targeting the apoptotic pathways offers a promising therapeutic strategy. This can be achieved by developing small molecules or biologic agents that restore the normal apoptotic process, such as BH3 mimetics, which inhibit anti-apoptotic proteins, or compounds that reactivate p53 function. Another strategy is to target the death receptor pathway, which can be activated to initiate apoptosis in resistant cells. By sensitizing MDR cancer cells to apoptotic signals, therapies that target these pathways can enhance the efficacy of

chemotherapy and prevent resistance development, leading to better clinical outcomes for cancer patients.(24)

1.13 Immunotherapy as an Adjunct to Traditional Chemotherapy

Immunotherapy has emerged as a promising adjunct to traditional chemotherapy in the fight against cancer, especially in the context of overcoming multidrug resistance (MDR). Unlike chemotherapy, which directly targets cancer cells, immunotherapy harnesses the body's immune system to identify and destroy cancer cells. In combination with chemotherapy, immunotherapy can enhance the immune response, enabling it to better recognize and target MDR cancer cells that have become resistant to standard chemotherapeutic agents.(25) One of the key mechanisms by which immunotherapy helps overcome MDR is by boosting the immune system's ability to detect cancer cells that may be evading traditional treatments. Immune checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4 inhibitors, work by blocking immune-suppressive signals that prevent the immune system from attacking cancer cells. Additionally, monoclonal antibodies and cancer vaccines can target specific tumor antigens and stimulate a targeted immune response. When combined with chemotherapy, these immune-based therapies can overcome the tumor's defense mechanisms, enhance drug efficacy, and potentially prevent the recurrence of drug-resistant cancer cells. Early clinical trials have demonstrated that combining immunotherapy with chemotherapy can improve patient outcomes in various cancers, including lung, breast, and melanoma.(26)

1.14 Personalized Medicine Approaches to Overcome Drug Resistance

Personalized medicine, or precision medicine, is an approach that tailors treatment to the individual characteristics of each patient, such as genetic profile, tumor mutations, and drug sensitivity. In the context of overcoming multidrug resistance (MDR), personalized medicine plays a crucial role by identifying specific molecular mechanisms driving resistance in a patient's cancer. By utilizing techniques like next-generation sequencing (NGS) and biomarker analysis, clinicians can identify genetic mutations and alterations in cancer cells that contribute to MDR, such as overexpression of drug efflux pumps, mutations in tumor suppressor genes, or changes in drug metabolism.(27) Once the resistance mechanisms are understood, targeted therapies can be selected to specifically counteract those pathways, offering a more effective treatment plan tailored to the patient's tumor biology. Additionally, personalized medicine involves selecting the most effective chemotherapy drugs or drug combinations based on a patient's tumor profile, minimizing the risk of resistance and maximizing therapeutic benefit. Advances in liquid biopsy and molecular profiling technologies have made personalized medicine more accessible, allowing for more precise treatments that improve survival and reduce unnecessary side effects. By focusing on the unique genetic landscape of each patient's cancer, personalized medicine offers a promising solution to overcome MDR and enhance the effectiveness of cancer therapies.(28)

1.15 Challenges and Limitations in Overcoming MDR in Cancer

Despite significant progress in understanding and addressing multidrug resistance (MDR) in cancer, there are several challenges and limitations that hinder the effective management of MDR in clinical settings. One major obstacle is the complex and multifactorial nature of MDR. Cancer cells can employ multiple resistance mechanisms simultaneously, making it difficult to pinpoint a single therapeutic target. Efflux pumps, enhanced DNA repair, mutations in drug targets, and altered apoptotic pathways can all contribute to resistance, and targeting just one of these pathways may not be sufficient to overcome MDR.(29) Additionally, tumor heterogeneity—the presence of different subpopulations of cancer cells within the same tumor—further complicates treatment strategies. Some subpopulations may remain resistant to therapy even if others are sensitive, leading to disease recurrence and progression.

Another significant challenge is the difficulty in delivering effective therapies to the tumor site. Many of the novel strategies designed to overcome MDR, such as nanoparticle-based drug delivery and gene therapy, face challenges related to delivery efficiency, off-target effects, and toxicity. The tumor microenvironment (TME), with its hypoxic conditions, high interstitial pressure, and dense extracellular matrix, can also limit the penetration of drugs, including those designed to overcome resistance.(30)

Strategy	Description	Advantages
Efflux Pump Inhibition	Targeting efflux pumps such as P-glycoprotein to prevent drug expulsion from cancer cells.	Reverses the effects of drug expulsion, improving drug retention.
Nanoparticle-Based Drug Delivery	Using nanoparticles to encapsulate drugs and deliver them specifically to resistant cancer cells.	Enhances drug stability and delivery, reducing side effects and improving efficacy.
Combination Therapy	Combining multiple drugs or therapies to target different pathways involved in drug resistance.	Prevents resistance by targeting multiple pathways simultaneously.
Gene Therapy	Introducing or modifying genes within cancer cells to overcome resistance mechanisms.	Directly addresses the genetic causes of resistance, offering precision-based solutions.
RNA Interference	Using small RNA molecules like siRNA or miRNA to silence genes responsible for resistance.	Specifically silences MDR-related genes, improving drug efficacy.
Targeting Apoptotic Pathways	Restoring or enhancing apoptosis in cancer cells to counteract their resistance to drug-induced cell death.	Sensitizes resistant cells to chemotherapy and restores cell death pathways.
Immunotherapy	Boosting the immune systemâ€™s ability to target and destroy drug-resistant cancer cells.	Improves cancer cell recognition and destruction by the immune system.
Personalized Medicine	Tailoring treatments based on genetic and molecular profiling to select drugs that overcome resistance in individual patients.	Enables more precise targeting, reducing unnecessary drug exposure and side effects.
Tumor Microenvironment Modulation	Targeting the tumor microenvironment to enhance drug delivery and sensitize cancer cells to therapy.	Improves drug delivery and overcomes physical barriers in the TME, enhancing therapy response.

CONCLUSION

Multidrug resistance (MDR) in cancer remains one of the most formidable challenges in oncology, significantly hindering the effectiveness of chemotherapy and contributing to poor clinical outcomes. The multifactorial nature of MDR, driven by complex mechanisms such as drug efflux, altered drug metabolism, DNA repair, and evasion of apoptotic pathways, makes it difficult to address through conventional treatment strategies. However, significant progress has been made in understanding the molecular basis of MDR, and novel approaches, including nanoparticle-based drug delivery, combination therapies, gene therapy, immunotherapy, and personalized medicine, offer promising avenues to overcome this resistance.

Although the integration of these innovative strategies into clinical practice is still developing, their potential to restore drug sensitivity, enhance therapeutic efficacy, and reduce the risk of resistance emergence is becoming increasingly evident. Personalized medicine, in particular, holds promise for tailoring therapies based on individual genetic and molecular profiles, ensuring more effective and targeted treatments for patients. Moreover, combining traditional chemotherapy with newer approaches like immunotherapy and gene silencing can synergistically combat MDR, improving patient outcomes.

Nevertheless, challenges remain, including the complexity of tumor heterogeneity, limitations in drug delivery, the rapid development of resistance, and the high cost and complexity of implementing personalized treatment strategies. Overcoming these challenges will require continued research and innovation, along with the development of more refined technologies for drug delivery, molecular profiling, and monitoring of resistance mechanisms. Ultimately, the fight against MDR in cancer is an ongoing journey. As new therapies are developed and existing strategies are optimized, there is hope for more effective cancer treatments that will not only overcome MDR but also improve survival rates and quality of life for patients worldwide.

REFERENCES:

1. Ahmad A, Sarkar SH, Li Y, et al. Targeting multidrug resistance in cancer: Recent

advances and perspectives. Cancer Lett. 2012;318(2):135-145.
2. Almeida L, Franco M, Silva S, et al. Nanoparticle-based drug delivery systems for overcoming multidrug resistance in cancer. J Control Release. 2014;192:38-54.
3. Anwar S, Bukhari NI, Siddiqui NA, et al. Role of efflux pumps in multidrug resistance and their inhibition in cancer cells. Crit Rev Oncol Hematol. 2018;123:19-28.
4. Ashrafizadeh M, Mohammadinejad R, Farkhondeh T, et al. Chemotherapy resistance in cancer: Mechanisms and overcoming strategies. J Cell Physiol. 2020;235(12):8545-8557.
5. Barok M, Isola J. P-glycoprotein in breast cancer. Eur J Cancer. 2012;48(4):610-616.
6. Bao ZS, Zhang J, Wang Y, et al. Clinical application of gene therapy in multidrug-resistant cancer. Chin J Cancer. 2017;36(1):40.
7. Basak D, Saha B, Ghosh K. Nanoparticles for the treatment of multidrug-resistant cancer: Approaches and challenges. Nanomedicine. 2021;16(15):1367-1383.
8. Bessone F, Medina M, D'Atri LP, et al. Multidrug resistance reversal strategies in cancer treatment. Int J Mol Sci. 2020;21(16):5764.
9. Bezerra DPF, Silva TM, da Costa VV, et al. Immunotherapy as an adjuvant to chemotherapy in multidrug-resistant cancers: Mechanisms and clinical implications. Front Oncol. 2019;9:1321.
10. Bhattacharya R, Sadhukhan P, Chakraborty S, et al. Targeted therapy for multidrug resistance: A review on the challenges, targets, and strategies. Eur J Pharmacol. 2016;773:202-213.
11. Chang Y, Han Y, Lee M, et al. Combination therapy strategies in cancer treatment: Overcoming multidrug resistance and improving therapeutic efficacy. Front Oncol. 2017;7:49.
12. Choi H, Kim M, Seo H, et al. Recent advances in overcoming multidrug resistance in cancer. Biol Pharm Bull. 2020;43(3):376-384.
13. Chouhan S, Bansal A, Verma P, et al. Genetic targeting of multidrug resistance in cancer: Advancements and challenges. Gene Ther. 2019;26(5):163-175.
14. Cinatl J, Vogel JU, Michaelis M, et al. Overcoming multidrug resistance in cancer through nanoparticle-based drug delivery systems. J Cancer. 2017;8(6):1147-1155.
15. Cuciureanu M, Paul A, Stanciu M, et al. Role of efflux pumps and epigenetic regulation in cancer drug resistance. J Drug Target. 2021;29(3):321-333.
16. Dastjerdi S, Yazdani N, Gheysari H, et al. Nanotechnology-based strategies to overcome multidrug resistance in cancer therapy. Eur J Pharm Sci. 2018;119:314-324.
17. Diaz-Gomez L, Carmona R, Saiz E, et al. Strategies to overcome multidrug resistance in cancer: Nanoparticles and beyond. Cancers. 2020;12(8):2246.
18. dos Santos R, Oliveira PR, Ferreira LS, et al. The role of RNA interference in overcoming multidrug resistance in cancer. J Control Release. 2022;348:109-122.
19. Dou Y, Liu Q, Xiang H, et al. Overcoming multidrug resistance in cancer with new strategies: Nanomedicine and gene therapy. J Control Release. 2021;329:566-583.
20. Duan Y, Xie S, Liu J, et al. Immunotherapy combined with chemotherapy: A new strategy to overcome multidrug resistance in cancer. Oncol Lett. 2019;18(4):3624-3631.
21. Emami F, Hushmandi K, Sadeghian M, et al. Modulation of drug resistance in cancer: A focus on efflux pumps. Front Oncol. 2020;10:501.
22. Fouladian P, Izadi S, Vafaei S, et al. Overcoming multidrug resistance in cancer: Nanomedicine strategies. J Drug Deliv Sci Technol. 2022;75:103595.
23. Geng X, Wang X, Zhang X, et al. Role of apoptotic pathways in multidrug-resistant cancer: Challenges and opportunities. Curr Drug Targets. 2016;17(6):718-726.
24. Gupta A, Chen Q, Sharma N, et al. Overcoming multidrug resistance in cancer: The role of targeted drug delivery systems. Eur J Med Chem. 2020;189:112016.
25. He Y, Zhang X, Xiao H, et al. Nanoparticle-based systems for overcoming multidrug

resistance in cancer therapy. Nanomedicine. 2019;14(3):487-505.
26. Jain P, Bansal R, Yadav S, et al. Combining chemotherapy and nanomedicine to overcome drug resistance in cancer. Eur J Pharm Sci. 2020;141:105074.
27. Kang J, Kim J, Lee Y, et al. Overcoming multidrug resistance in cancer via synergistic combination therapies. Drug Resist Updat. 2021;56:100759.
28. Li H, Wang Y, Wang Y, et al. Multidrug resistance mechanisms in cancer and their implications for novel drug development. Front Pharmacol. 2022;13:795518.
29. Ma L, Liu H, Liu T, et al. The role of the tumor microenvironment in multidrug resistance in cancer. Front Pharmacol. 2019;10:310.
30. Zhang L, He W, Zhang X, et al. Overcoming multidrug resistance in cancer through immunotherapy and targeted therapies. Pharmacol Ther. 2023;237:108159.

*****